Sign in

    Solve

    Research Analyst at RBC Capital Markets

    Solve is an Analyst at RBC Capital Markets, specializing in equity research with a focus on specific industry sectors. Details regarding the exact companies covered, performance metrics, and quantitative achievements are not publicly available. Solve’s career timeline, previous firms, and professional credentials such as securities licenses or rankings are not verifiable from accessible sources. Comprehensive information about their professional profile remains limited due to the lack of publicly disclosed data.

    Solve's questions to Moderna (MRNA) leadership

    Solve's questions to Moderna (MRNA) leadership • Q1 2025

    Question

    Solve, on for Luca Issi, asked about recent political commentary on single-antigen vaccines and sought reassurance that Moderna's upcoming PDUFAs would be reviewed based on science rather than politics.

    Answer

    President Stephen Hoge affirmed the company's confidence in its robust clinical data and the scientific review process. He stated that interactions with the FDA have been "business as usual" and are based on large, randomized efficacy studies. He also noted that Moderna develops both single-antigen and multi-antigen products, believing in the value of both approaches.

    Ask Fintool Equity Research AI